Effect of Dexmedetomidine on Acute Kidney Injury After Ascending Aortic Surgeries

Condition(s) studied

Investigational drug(s) / intervention(s)

Dexmedetomidine: the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.

Normal Saline (Placebo): Group (B): the control group will receive an infusion of an equivalent volume of a 0.9% saline for the same duration

Study summary

Acute kidney injury (AKI) is a frequent and serious complication after ascending aortic surgeries requiring cardiopulmonary bypass (CPB). Dexmedetomidine, a selective α-2 adrenoreceptor agonist, may reduce AKI because of its sympatholytic and anti-inflammatory effects against ischaemia reperfusion injury. We investigate the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.

Eligibility

Primary outcome measure(s)

• measurement of kidney function — Serum creatinine levels will beassessed before surgery, at least once a day until postoperative day 5
  AKI will be diagnosed based on the AKIN criteria: Stage 1 was defined as a serum creatinine increase ≥1.5-2-fold above baseline or ≥0.3 mg/dl or urine output \<0.5 ml/kg/h for \>6 h; stage 2 was defined as a creatinine increase \>2-3-fold above baseline or urine output \<0.5 ml/kg/h for \>12 h; stage 3 was defined as a creatinine increase \>3-fold above baseline or \>4.0 mg/dl with an acute increase of 0.5 mg/dl, urine output \<0.3 ml/kg/h for 24 h, or anuria for 12 h

Trial sites (1)

More Ain Shams University trials in Egypt